v3.26.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Significant Expense Categories (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Revenue $ 0   $ 1,300   $ 0 $ 1,300
Research and development expense            
Total research and development expense (23,899)   (22,267)   (49,116) (59,144)
General and administrative expense            
Total general and administrative expense (8,250)   (6,422)   (13,960) (12,446)
Other expense (4,498)   (1,263)   (7,012) (1,673)
Provision for income taxes (3)   (2)   (3) (2)
Net loss (36,650) $ (33,441) (28,654) $ (43,311) (70,091) (71,965)
Reportable Segment            
Segment Reporting [Line Items]            
Revenue 0   1,300   0 1,300
Research and development expense            
Personnel (8,017)   (8,637)   (16,543) (17,963)
Clinical trials (5,285)   (4,082)   (14,465) (17,347)
Contract manufacturing (5,418)   (3,828)   (7,461) (12,378)
Equipment, depreciation, and facility (2,489)   (2,563)   (5,051) (5,146)
Other research and development (2,690)   (3,157)   (5,596) (6,310)
General and administrative expense            
Personnel (4,073)   (3,655)   (7,720) (7,432)
Other general and administrative (4,177)   (2,767)   (6,240) (5,014)
Total general and administrative expense (8,250)   (6,422)   (13,960) (12,446)
Other expense (4,498)   (1,263)   (7,012) (1,673)
Provision for income taxes $ (3)   $ (2)   $ (3) $ (2)